meRfi®-GM
Atezolizumab
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Atezolizumab - a fully humanized IgG1 mAb blocking interaction of PD-L1 with both PD-1 and B7.1, but not interaction of PD-L2 with [PD-1]
PD-L1 is a protein that hinders the immune system from attacking cancer cells. By doing so, it aims to reactivate the immune response to fight the cancer and inhibit its growth
Atezolizumab is approved for the treatment of non-small cell lung cancer (NSCLC) and advanced liver cancer (hepatocellul…
References (Sources)
- Atezolizumab in urothelial bladder carcinoma
- Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
- IMpower150 study group Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Second- and third-generation drugs for immuno-oncology Treatment - The more the better?
- Spotlight on atezolizumab and its potential as an oncology agent
- The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderlyReview